A Retrospective Study of Clinical Response Predictors in Subcutaneous Allergen Immunotherapy With House Dust Mites for Allergic Rhinitis
10.4168/aair.2018.10.1.18
- Author:
Ji Ho LEE
1
;
Su Chin KIM
;
Hyunna CHOI
;
Chang Gyu JUNG
;
Ga Young BAN
;
Yoo Seob SHIN
;
Dong Ho NAHM
;
Hae Sim PARK
;
Young Min YE
Author Information
1. Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea. ye9007@ajou.ac.kr
- Publication Type:Original Article
- Keywords:
Allergen-specific immunotherapy;
house dust mites;
remission;
rhinitis, allergic
- MeSH:
Adult;
Allergens;
Aluminum;
Anaphylaxis;
Asthma;
Desensitization, Immunologic;
Dust;
Humans;
Hypersensitivity;
Immunoglobulin E;
Immunoglobulins;
Immunotherapy;
Incidence;
Life Tables;
Medical Records;
Pollen;
Pyroglyphidae;
Retrospective Studies;
Rhinitis, Allergic;
Tertiary Care Centers
- From:Allergy, Asthma & Immunology Research
2018;10(1):18-24
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: House dust mites (HDM) are major allergens that cause allergic rhinitis (AR). Allergen-specific subcutaneous immunotherapy (SCIT) has been shown to be clinically beneficial in many clinical trials. Such trials, however, are not reflective of all patient populations. The aim of this study was to describe the efficacy and safety of SCIT in routine clinical practice in Korean adults with AR sensitized to HDM. METHODS: We reviewed medical records of 304 patients with AR treated at an allergy clinic of a tertiary hospital using SCIT with aluminum hydroxide-adsorbed allergen extract targeting HDM alone or with pollens for at least 1 year from 2000 to 2012. Patients with asthma were excluded. Rates of remission, defined as no further requirement of maintenance medication, over time were determined by means of life tables and extension of survival analysis. Specific immunoglobulin E (IgE) levels to HDM were categorized into 6 classes. RESULTS: The mean time until achieving remission was 4.9±0.1 years, and the cumulative incidence of remission from AR was 76.6%. Severe AR (odds ratio [OR], 0.40; 95% confidence interval [CI], 0.23-0.69; P=0.001), specific IgE levels to HDM ≥17.5 kU/L (OR, 1.85; 95% CI, 1.01-3.37; P=0.045), and duration of immunotherapy ≥3 years (OR, 7.37; 95% CI, 3.50-15.51; P<0.001) were identified as significant predictors of clinical remission during SCIT for patients with AR sensitized to HDM. Overall, 73 patients (24.0%) experienced adverse reactions to SCIT, and only 1 case of anaphylaxis (0.3%) developed. CONCLUSIONS: SCIT with HDM was found to be effective and safe for patients with AR. Specific IgE levels to HDM and a duration of SCIT ≥3 years may be predictors of clinical responses to SCIT in AR patients.
